View clinical trials related to Transgender Persons.
Filter by:Transgender male (TM) is the minority and difficult to reach-up group. Therefore, there is a lack of research on private issues involving TM, such as sex, eroticism, and sexual risk behavior. This study focuses on TM as the research participant, based on Milton Mayeroff's caring theory, to understand the TM's erotic culture and the sexual risks behavior, to evaluate the need for subsequent sexual health care. The research method is a mixed methods research of explanatory design, which recruits participants through purposive sampling and respondent-driven sample (RDS) methods. The first stage is an online questionnaire survey. A total of 321 TMs were recruited. The time of online questionnaire is about 10-15 minutes to get a preliminary understanding of the erotic and sexual risk experience of TM in Taiwan. In the second stage, focus groups and in-depth interviews will be conducted, 2 hours of each group and interview. A total of 29 transgender man and women, and non-binary participants were recruited. The recruitment will be stop when the data are saturated. The analysis of both quantitative and qualitative data can get an in-depth understanding of sex, eroticism, and sexual risk, and violence experiences of the participants. The research results are important for improving the awareness and identification of sexual risk and the assessment of sexual health care needs of TM in health care profession. The results also serve as a reference guide for the development of care needs on sexual health care and anti-violence of transgender people, and for the implement of a gender-friendly environment for medical care.
During the COVID-19 outbreak, it was necessary to remodel the healthcare offer for all categories of subjects in order to minimize unnecessary movements of people while maintaining an adequate level of assistance. This is also true for transgender people, who are periodically requested to come into the clinic for hormonal therapy monitoring and continuation. In our center telemedicine programs dedicated to users have been activated for the remote management of hormone therapy. We use a web-based survey to assess the impact of COVID-19 outbreak on trans-population health and to assess the specific needs of this population in this particular moment.
Blogs, word-of-mouth, and small studies from the 1990s in the premature ovarian insufficiency and menopause populations have suggested sublingual or transdermal estradiol may be safer and/or more effective than an oral formulation. Sublingual administration entails holding the estrogen tablet under the tongue and allowing it to dissolve, where its absorption is enhanced by the rich vascularization under the tongue. According to Price et al., sublingual administration results in rapid absorption with significantly higher estradiol levels than does comparable oral dosing. This is likely because sublingual administration will bypass metabolism by the intestines and liver. The transdermal route, which also bypasses first-pass metabolism, is not associated with an increased venous thromboembolic risk nor a significant increase in plasma triglycerides or HDL-cholesterol levels. As such, transdermal estrogen is often preferred over oral formulations, although it is relatively expensive and not accessible to many transgender women. Conversely, sublingual administration of estrogen tablets is widely available and could be a cost-effective alternative to transdermal estrogen. However, there are no well-conducted studies that have evaluated the safety and efficacy of sublingual estrogen therapy in the transgender population. This pilot study will elucidate how estrogen levels in the blood change following sublingual versus oral administration of estradiol in transgender women. This data may be used later to design larger studies on safety and efficacy. Additionally, analyzing a dosage method that patients themselves have tried independently and found effective is also important. This approach incorporates intelligence from the transgender community into our research, creating new knowledge that is supported by data but is founded in existing community insights. Thus, the outcomes of this research have the potential to integrate patient input while also aiding in the development of safety recommendations, with the goal of better caring for our transgender patients. Primary aim. To establish the pharmacokinetics of sublingual estradiol versus oral estradiol in transgender women.
The trial studies the efficacy of subcutaneous (SQ) testosterone compared to intramuscular (IM) testosterone therapy during the first 6 months of pubertal induction in transgender male adolescents. Describes rate of adverse effects, masculinizing effects and quality of life while receiving testosterone. Evaluates clinic utilization required for testosterone therapy.
The Stay Study is a multi-site, open-label HIV pre-exposure prophylaxis (PrEP) demonstration project for advancing PrEP delivery in the San Francisco Bay Area Transgender Community. Approximately 188 HIV-uninfected participants will be enrolled at 4 sites in San Francisco and Fremont and will be provided Truvada to take orally once daily as PrEP.